Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia
Background Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.Objectives To identify physicians’ prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of bi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2386973 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850249983353159680 |
|---|---|
| author | Ahmad Alamer Wejdan Alyazidi Saad Aldosari Fatimah Mobarki Sarah Almakki Abdullah Alahmari Mukhtar Alomar Ziyad Almalki Tuqa Alkaff Mohammad Fazel |
| author_facet | Ahmad Alamer Wejdan Alyazidi Saad Aldosari Fatimah Mobarki Sarah Almakki Abdullah Alahmari Mukhtar Alomar Ziyad Almalki Tuqa Alkaff Mohammad Fazel |
| author_sort | Ahmad Alamer |
| collection | DOAJ |
| description | Background Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.Objectives To identify physicians’ prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of biologic persistence following treatment initiation.Methods We conducted a retrospective study of biologic-naïve adult psoriasis patients who initiated therapy from October 2013 to July 2022 in Dammam. Descriptive statistics and a Kaplan-Meier analysis evaluated treatment persistence at 6, 12, 24, and 36 months.Results A total of 151 patients received adalimumab (n = 89), etanercept (n = 17), risankizumab (n = 30), ustekinumab (n = 14), and ixekizumab (n = 1). At 6 months, all therapies demonstrated 100% persistence. At 12 months, persistence was highest for ustekinumab (100%) and lowest for etanercept (88.2%). At 24 months, ustekinumab maintained 100% persistence, followed by risankizumab (96.6%), adalimumab (94.3%), and etanercept (76.4%). At 36 months, risankizumab had the highest persistence (96.6%), followed by adalimumab (83.1%), ustekinumab (78%), and etanercept (70.6%). The most common reasons for discontinuation were lack of effectiveness and intolerability.Conclusion This study shows changing psoriasis treatment patterns with new therapies. Risankizumab demonstrated high long-term persistence, while etanercept and ustekinumab showed declining persistence, suggesting evolving treatment considerations. |
| format | Article |
| id | doaj-art-29515769a21f4b3ba18416eef1ed331f |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-29515769a21f4b3ba18416eef1ed331f2025-08-20T01:58:20ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2386973Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi ArabiaAhmad Alamer0Wejdan Alyazidi1Saad Aldosari2Fatimah Mobarki3Sarah Almakki4Abdullah Alahmari5Mukhtar Alomar6Ziyad Almalki7Tuqa Alkaff8Mohammad Fazel9Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi ArabiaPharmaceutical Care Services, Eastern Health Cluster, Dammam, Saudi ArabiaDepartment of Clinical Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi ArabiaPharmaceutical Care Services, Eastern Health Cluster, Dammam, Saudi ArabiaPharmaceutical Care Services, Eastern Health Cluster, Dammam, Saudi ArabiaDepartment of Clinical Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi ArabiaPharmaceutical Care Services, Eastern Health Cluster, Dammam, Saudi ArabiaDepartment of Clinical Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi ArabiaDepartment of Dermatology, Allure Clinics, Riyadh, Saudi ArabiaDivision of Dermatology/Banner, University of Arizona, Tucson, Arizona, USABackground Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.Objectives To identify physicians’ prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of biologic persistence following treatment initiation.Methods We conducted a retrospective study of biologic-naïve adult psoriasis patients who initiated therapy from October 2013 to July 2022 in Dammam. Descriptive statistics and a Kaplan-Meier analysis evaluated treatment persistence at 6, 12, 24, and 36 months.Results A total of 151 patients received adalimumab (n = 89), etanercept (n = 17), risankizumab (n = 30), ustekinumab (n = 14), and ixekizumab (n = 1). At 6 months, all therapies demonstrated 100% persistence. At 12 months, persistence was highest for ustekinumab (100%) and lowest for etanercept (88.2%). At 24 months, ustekinumab maintained 100% persistence, followed by risankizumab (96.6%), adalimumab (94.3%), and etanercept (76.4%). At 36 months, risankizumab had the highest persistence (96.6%), followed by adalimumab (83.1%), ustekinumab (78%), and etanercept (70.6%). The most common reasons for discontinuation were lack of effectiveness and intolerability.Conclusion This study shows changing psoriasis treatment patterns with new therapies. Risankizumab demonstrated high long-term persistence, while etanercept and ustekinumab showed declining persistence, suggesting evolving treatment considerations.https://www.tandfonline.com/doi/10.1080/09546634.2024.2386973Patternspersistencebiological therapiespsoriasis |
| spellingShingle | Ahmad Alamer Wejdan Alyazidi Saad Aldosari Fatimah Mobarki Sarah Almakki Abdullah Alahmari Mukhtar Alomar Ziyad Almalki Tuqa Alkaff Mohammad Fazel Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia Journal of Dermatological Treatment Patterns persistence biological therapies psoriasis |
| title | Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia |
| title_full | Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia |
| title_fullStr | Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia |
| title_full_unstemmed | Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia |
| title_short | Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia |
| title_sort | prescribing patterns and persistence of biological therapies for psoriasis management a retrospective cohort study from saudi arabia |
| topic | Patterns persistence biological therapies psoriasis |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2386973 |
| work_keys_str_mv | AT ahmadalamer prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT wejdanalyazidi prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT saadaldosari prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT fatimahmobarki prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT sarahalmakki prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT abdullahalahmari prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT mukhtaralomar prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT ziyadalmalki prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT tuqaalkaff prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia AT mohammadfazel prescribingpatternsandpersistenceofbiologicaltherapiesforpsoriasismanagementaretrospectivecohortstudyfromsaudiarabia |